Catalyst Pharmaceuticals (CPRX) Free Cash Flow (2010 - 2026)

Catalyst Pharmaceuticals has reported Free Cash Flow for 17 years, with the latest figure at $59.6 million in Q1 2026.

• For the quarter ending Q1 2026, Free Cash Flow fell 0.8% year-over-year to $59.6 million; the trailing twelve-month figure through Mar 2026 stood at $208.1 million (down 22.21% YoY), and the FY2025 full-year result was $208.6 million, down 12.81% from the prior year.
• Free Cash Flow for Q1 2026 stood at $59.6 million, up from $44.9 million in the prior quarter.
• The five-year high for Free Cash Flow was $72.6 million in Q3 2024, with the low at $8.5 million in Q1 2022.
• Historically, Free Cash Flow has averaged $45.1 million across 5 years, with a median of $44.9 million in 2025.
• Annual changes were most pronounced in 2022 — Free Cash Flow jumped 192.04% — and 2025, when it slumped 55.33%.
• Catalyst Pharmaceuticals' Free Cash Flow stood at $40.1 million in 2022, then jumped by 38.62% to $55.6 million in 2023, then gained by 27.42% to $70.8 million in 2024, then sank by 36.63% to $44.9 million in 2025, then surged by 32.77% to $59.6 million in 2026.
• The last three Free Cash Flow figures came in at $59.6 million (Q1 2026), $44.9 million (Q4 2025), and $32.4 million (Q3 2025), per Business Quant data.